How Do Driver Mutations Influence Cancer Treatment?
Driver mutations have a significant impact on cancer treatment. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are designed to specifically inhibit the activity of proteins encoded by mutated oncogenes. For instance, mutations in the EGFR gene in non-small cell lung cancer (NSCLC) can be targeted by EGFR inhibitors, leading to improved clinical outcomes. Similarly, understanding the molecular landscape of a tumor can guide the selection of appropriate therapies, reducing toxicity and increasing efficacy.
